Bruce Quinn joins FaegreBD Consulting

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BRUCE QUINN joined FaegreBD Consulting as a senior director with the firm’s health and biosciences team in Washington, D.C., where he leads the firm’s health markets and reimbursement strategy consulting practice. Quinn is a national leader on Medicare policy, the impact of health reform on innovation and the crafting of successful business strategies within the...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login